What this is
- This research investigates the association between () levels and the risk of ().
- The study involved 6,767 US adults free of at baseline, followed over a median of 11.3 years.
- , a metabolite derived from gut microbiota, was measured at baseline and again at five years to assess its impact on cardiovascular events.
Essence
- Higher plasma levels are linked to an increased risk of in a diverse, multi-ethnic population. The association is dose-dependent, suggesting that may play a significant role in cardiovascular risk.
Key takeaways
- levels were associated with a higher risk of , with hazard ratios of 1.02, 1.17, 1.23, and 1.33 across increasing quintiles compared to the lowest quintile. This indicates a dose-dependent relationship.
- The study found that the risk associated with appeared larger among Hispanic and Chinese adults, although these differences did not reach statistical significance. This suggests potential variability in 's impact across different ethnic groups.
- The association remained significant even after adjusting for various cardiovascular risk factors, indicating that 's effects on risk may extend beyond traditional risk factors.
Caveats
- The observational nature of the study may allow for residual confounding, as not all potential influencing factors were measured. This could impact the strength of the observed associations.
- Data on gut microbiota composition and other factors influencing production were not collected, which could provide additional context for the findings.
- The findings are based on a US-based population, which may limit generalizability to other regions or populations.
Definitions
- Trimethylamine-N-oxide (TMAO): A gut microbiome-derived metabolite from dietary choline and related nutrients, associated with cardiovascular disease risk.
- Atherosclerotic cardiovascular disease (ASCVD): A range of conditions involving narrowed or blocked arteries due to atherosclerosis, leading to heart attacks and strokes.
AI simplified
Condensed abstract
Trimethylamine-N-oxide (TMAO) is a gut microbiome-derived metabolite of nutrients more abundant in animal source foods. We evaluated 6,767 US adults free of ASCVD at baseline in the population-based Multi-Ethnic Study of Atherosclerosis. Plasma TMAO was measured at baseline, and its association with incident atherosclerotic cardiovascular events over 11.3 years. In multivariate models, TMAO was associated with higher risk of ASCVD, with HRs across quintiles of 1.02, 1.17, 1.23, and 1.33 (95% CI 1.02, 1.74), respectively, compared to the lowest quintile (P-trend = 0.01). Plasma TMAO was associated with higher risk of incident ASCVD in this multi-ethnic cohort of middle-aged U.S. adults.
Growing evidence supports an important role of gut microbiota in the development of atherosclerosis cardiovascular disease (ASCVD)1–4. Trimethylamine N-oxide (TMAO) is a gut microbiota-derived metabolite of dietary choline, L-carnitine, and phosphatidylcholine (lecithin)-rich animal foods (e.g., especially red meat and eggs; also fish and poultry). Based on experimental animal studies, combined with numerous clinical studies of high risk patients enriched with prevalent disease, elevated plasma TMAO may increase risk of ASCVD5–10. However, very few studies have examined the relationship of TMAO with onset of ASCVD in a well-characterized, community-based multi-ethnic cohort free of ASCVD at baseline89.) This extensively phenotyped Multi-Ethnic Study of Atherosclerosis has advantages of it’s longitudinal nature, carefully adjudicated outcomes, multiple measures of TMAO, and racial/ethnic diversity. Understanding the epidemiology of the effect of TMAO on ASCVD is important, and elucidating these relationships is important to understand the generalizability of potential effects of TMAO across different race/ethnicity groups (as risk factor prevalence, social determinants of health and atherosclerosis severity all vary by race/ethnicity), and to address the potential for confounding and reverse causation in clinical samples of high risk patients with prevalent disease. In addition, TMAO levels are known to change over time due to variation in diet, the microbiome, and metabolism. Few studies have assessed ASCVD risk using baseline and 5-year follow-up measures of TMAO over time, rather than a single baseline measure.
To address these gaps, we investigated whether baseline and 5-year follow-up measures of plasma TMAO were associated with incident ASCVD risk in the MESA, a large prospective, community-based, multi-racial/ethnic cohort with extensive phenotyping. We hypothesized that higher levels of plasma TMAO would be associated with higher ASCVD risk.
Methods
Study design and recruitment
MESA11 is a longitudinal, population-based cohort study of incident ASCVD funded by the National Heart, Lung, and Blood Institute. A total of 6,814 men and women, aged 45–84 years and free of clinical cardiovascular disease at baseline, were recruited from six Field Centers in Baltimore, MD; Chicago, IL; Forsyth County, NC; Los Angeles, CA; New York, NY; and St. Paul, MN. Racial/ethnic groups enrolled included White, Black, Hispanic, and Chinese adults. Approximately 50% of the participants enrolled were female. The baseline visit took place between July 2000 and September 2002, with in-person study follow-up visits approximately every 2.5 years. The study was approved by Institutional Review Boards at each site and informed consent was obtained from all participants and/or their legal guardians. This study was approved by the Institutional Review Board at the Lundquist Institute at Harbor-UCLA, Torrance CA. All research was performed in accordance with relevant guidelines/regulations, and in accordance with the Declaration of Helsinki.
Quantification of plasma TMAO
Serial plasma TMAO concentrations were measured using stored frozen (−80 ˚C) 12-h fasting blood samples collected at baseline (2000–2002; n = 6,796 participants) and exam 4 (2005–2007; n = 5633 participants) using established stable isotope dilution with on-line liquid chromatography tandem mass spectrometry (LC-MS/MS) methods12. Briefly, LC-MS/MS analyses were performed on a triple quadrupole mass spectrometer (LCMS-8050, Shimadzu Corporation, Kyoto, Japan) at the Cleveland Clinic Lerner Research Institute using d9(trimethyl)TMAO (d9-TMAO) as internal standards. TMAO and d9-TMAO were monitored using electrospray ionization in positive-ion mode with multiple reaction monitoring of parent and characteristic daughter ion transitions as previously described, including m/z 76.10 ◊59.10 and 76.10 ◊58.10 for TMAO, and 85.00◊ 66.15 and 85.00◊ 68.15 for d9-TMAO. At least three pooled quality control (QC) samples spanning between 0.5 μm and 200 μm TMAO levels were included with every batch (81 samples) analyzed. Assay performance metrics include laboratory intra-day and inter-day coefficient of variations for TMAO analyses that were < 6% across all QC samples; accuracy was > 97% for all pooled QC samples; Lower limit of detection = 0.02 μm, signal-to-noise ratio of 3 or greater; Lower limit of quantification = 0.05 μm, signal-to-noise ratio of 10 or greater; upper limit of quantification > 200 μm12.
We estimated time-varying TMAO exposure, with TMAO concentrations measured in 2000–2002 related to risk between 2000 and 2002 and 2005–2007, and the average of TMAO levels in 2000–2002 and 2005–2007, to risk from 2005 to 2007 through 2017. This specific approach for cumulative average has been widely used13–15 to reduce exposure misclassification due to within-subject variation in TMAO measures.
Ascertainment of ASCVD
MESA event surveillance and classification have been described16. Participants were seen at in-person study visits every 2–3 years, with additional telephone interview contacts at intervals of 9–12 months, to inquire about interim hospital admissions, cardiovascular outpatient diagnoses, and deaths. Self-reported diagnoses were verified using medical records for hospitalizations and outpatient visits, death certificates, and next-of-kin interviews for out-of-hospital cardiovascular deaths17. Records were obtained on 98% of reported hospitalized cardiovascular events18 and 95% of reported outpatient diagnostic encounters. Trained personnel abstracted medical records, and two physicians independently classified the events and assigned incidence dates, with any differences resolved via discussion. The primary outcome of the present investigation was incident ASCVD, including the first definite or probable MI, CHD death, fatal or nonfatal stroke (not transient ischemic attack), resuscitated cardiac arrest, other atherosclerotic death, or other cardiovascular death. Additional details on MESA’s follow-up methods and event adjudication are at http://www.mesa-nhlbi.org↗.
Covariates
At each study visit, standardized questionnaires collected data on age, sex, race/ethnicity, education, smoking, co-morbidities, and medications; physical examination was performed; and laboratory measurements were obtained. Smoking was categorized as never, former, or current; with current smoking further delineated as light (1–20 pack-years), moderate (20.1–40 pack-years), or heavy (> 40 pack-years). Habital dietary intake over the previous year was assessed at baseline using a 120-item self-administered food frequency questionnaire (FFQ) adapted to include Chinese cuisine20. Participants reported the frequency and usual serving size for each food item, based on which daily servings of fruits, vegetables, meat and alcohol were calculated21. Fasting glucose ≥ 126 mg/dL or hypoglycemic medication use defined diabetes mellitus. Resulting blood pressure (Dinamap model Pro 100) was assessed as the average of the second and third readings22. Height and weight were measured, and body mass index (BMI) calculated as weight (kg)/height (m) squared. Physical activity was ascertained using the MESA Typical Week Physical Activity Survey (TWPAS), identifying amounts of time spent in and frequency of various physical activities during a typical week in the prior month11. Minutes of activity were summed for each discrete type and multiplied by metabolic equivalent (MET) level. In our study, we used total intentional exercise. After an overnight fast, blood samples were collected to measure total cholesterol, high-density lipoprotein-cholesterol (HDL-C), and triglyceride levels; with LDL-C calculated using the Friedewald equation23. Using the colorimetric method and creatinine-based CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation, serum creatinine and estimated Glomerular Filtration Rate (eGFR) were calculated24. Family history of CVD was defined from self-reported history of myocardial infarction (MI) and stroke in first-degree relatives.
Statistical analyses
We evaluated associations between plasma TMAO concentrations and ASCVD using Cox proportional hazards models with time-at-risk until the first event, other death, or censoring at the last follow-up (PROC PHREG procedure SAS)25. We tested the proportional hazards assumption by using extended Cox models with product terms of TMAO and covariates with time-dependent log of time to ASCVD event, and found no evidence of violation for TMAO or any covariate except prevalent diabetes at baseline. We addressed this by incorporating diabetes as a risk-set stratification variable26.
To assess association of long-term TMAO exposure, we used time-varying TMAO concentrations, with TMAO measured at baseline related to incident events through 2005–2007, and the average of baseline and 2005–2007 TMAO related to events occurring after 2005–2007. For participants with only one baseline TMAO measure (17%), that measured was carried forward. We evaluated TMAO continuously using the interquintile median range (IQR, defined as the difference between the median of the fifth and first quintiles) and in quintiles as indicator variables. We assessed the presence of nonlinear relationships using restricted cubic splines. To minimize potential confounding, we considered pre-specified covariates based on biologic interest, risk factors for ASCVD, or associations with TMAO or ASCVD. Covariates included baseline sex, race/ethnicity, enrollment site, education, and income, and time-varying age, self-reported health status, smoking status, physical activity, BMI, waist circumference, prevalent diabetes, alcohol intake, HDL-C, LDL-C, triglycerides, C-reactive protein, systolic and diastolic blood pressure, use of lipid-lowering medication, use of anti-hypertensive medication, use of antibiotics within the 2 weeks preceding TMAO measurement, and habitual diet including intakes of animal source foods (the sum of unprocessed red meat, processed meat, eggs, chicken, and fish), fruits, vegetables, and dietary fiber. We included both BMI and waist circumference in our models to minimize residual confounding by adiposity; and both education and income to minimize confounding by socioeconomic status. Time-varying covariates were updated from exam 4. We conducted analysis adjusting for dietary risk factors to determine whether the potential association with TMAO could be attributed to TMAO-containing food sources or other dietary factors correlated with healthy eating patterns and/or TMAO concentrations. In sensitivity analyses, we adjusted for eGFR27, which could be a mediator or confounder of the TMAO-ASCVD association given that TMAO is renally cleared and that experimental models show that TMAO damages the kidney, increases cystatin C, and reduces eGFR28,29. Missing covariate data (generally < 1%) were imputed using multiple demographic and risk variables using single multivariable imputation; in prior analyses, we have shown that such methods provide results very similar to multiple imputation30. We explored potential effect modification by baseline age, sex as a biological variable, race/ethnicity as a self-reported social construct, BMI, and eGFR (< 60 vs. ≥ 60 mL/min/1.73m2). Statistical significance of each multiplicative interaction term was assessed using the Wald test, with p-values for these exploratory analyses Bonferroni adjusted for multiple comparisons (α = 0.05/5 = 0.01). Analyses otherwise utilized a two-tailed alpha = 0.05 and were performed using Stata, release 14.0 (StataCorp), and SAS, version 9.4 (SAS Institute).
Results
At baseline, mean (SD) age was 61.8 (10.1) years, and 38% of participants identified as White adults; 28%, Black; 22%, Hispanic; and 12%, Chinese (Table 1; Fig. 1). Mean plasma TMAO concentrations (mean ± SD µmol/L) were 5.2 ± 7.1 and 6.3 ± 9.2 at exams 1 and 4, respectively. The correlation between TMAO measures was moderate, with Spearman partial correlation coefficients adjusting for age, sex, and race-ethnicity, yielding a value of 0.35 (p-value < 0.001). Approximately 13% of participants had diabetes, 6% had low eGFR, 16% were taking lipid-lowering medications, 37% were on anti-hypertensive medications, and 3% had taken antibiotics in the previous 2 weeks. In crude (unadjusted) analyses across quintiles, those with higher circulating TMAO concentrations were more likely to be older and White; have diabetes, low eGFR, higher systolic blood pressure, and higher triglyceride levels; and be on lipid-lowering and anti-hypertensive medications.
STROBE diagram for patient characteristics. Abbreviations: MESA = Multiethnic Study of Atherosclerosis; TMAO = trimethylamine-oxide. N
Multivariate-adjusted relationships between plasma TMAO and ASCVD evaluated using restricted cubic splines. Knots were evaluated at the 10th, 50th, and 90th percentiles. Dotted vertical lines represent, from left to right, the 10th, 25th, 50th, 75th, and 90th percentiles of circulating TMAO. Covariates are specified in Table 2. The top 1% of the exposure distribution was omitted for better visualization.
Multivariate-adjusted relationships between plasma TMAO and ASCVD in key subgroups. Hazard ratios (and 95% confidence intervals) are shown for continuous analyses comparing the midpoint of the highest vs. lowest quintile of plasma TMAO among 6,765 US adults in the Multi-Ethnic Study of Atherosclerosis, stratified by sex, race/ethnicity, age, body mass index (BMI), and renal function (estimated glomerular filtration rate below or above 60 mL/min/1.73 m). 2
| Quintiles of TMAO | |||||
|---|---|---|---|---|---|
| Q1 | Q2 | Q3 | Q4 | Q5 | |
| n | 1,351 | 1,354 | 1,354 | 1,352 | 1,354 |
| Median TMAO ((10th, 90th)), µmol/L | 1.75 (1.09, 2.14) | 2.61 (2.29, 2.95) | 3.56 (3.14, 4.01) | 4.98 (4.32, 5.96) | 9.2 (6.67, 9.20) |
| Demographics | |||||
| Age, years | 59 (10) | 61 (10) | 63 (10) | 64 (10) | 65 (10) |
| Female, n (%) | 751 (55.6) | 760 (56.1) | 715 (52.8) | 668 (49.4) | 676 (49.9) |
| Race, n (%) | |||||
| White | 399 (29.5) | 523 (38.6) | 532 (39.3) | 579 (42.8) | 574 (42.4) |
| Asian | 216 (16) | 157 (11.6) | 151 (11.2) | 121 (9) | 156 (11.5) |
| Black | 402 (29.8) | 360 (26.6) | 377 (27.8) | 363 (26.9) | 366 (27) |
| Hispanic | 334 (24.7) | 314 (23.2) | 294 (21.7) | 289 (21.4) | 258 (19.1) |
| Lifestyle and other risk factors | |||||
| Income | |||||
| <$11,999 | 92 (6.8) | 74 (5.5) | 96 (7.1) | 77 (5.7) | 90 (6.6) |
| $12,000 to 24,999 | 226 (16.7) | 225 (16.6) | 266 (19.7) | 237 (17.5) | 237 (17.5) |
| $25,000 to $49,999 | 374 (27.7) | 357 (26.4) | 358 (26.4) | 399 (29.5) | 351 (25.9) |
| >$50,000 | 488 (36.1) | 510 (37.7) | 466 (34.4) | 470(34.8) | 469 (34.6) |
| ≥ 12 years of education | 966 (71.5) | 971 (71.7) | 963 (71.1) | 969 (71.7) | 929 (68.6) |
| Cigarette Smoking, n (%) | |||||
| Never | 709 (52.5) | 705 (52.1) | 663 (49.0) | 666 (49.3) | 659 (48.7) |
| Former | 436 (32.3) | 475 (35.1) | 522 (38.5) | 521 (38.5) | 526 (38.8) |
| Current | 206 (15.2) | 174 (12.8) | 169 (12.5) | 165 (12.2) | 169 (12.5) |
| Physical activity), MET-min/week | 1557 (2166) | 1544 (2275) | 1633 (2775) | 1567 (2302) | 1479 (2135) |
| Alcohol, drinks/week | 2.4 (5) | 2.8 (5.8) | 2.6 (4.9) | 2.7 (5.3) | 2.6 (5.2) |
| BMI, kg/m2 | 27.6 (5.6) | 28.2 (5.3) | 28.3 (5.4) | 28.9 (5.6) | 28.6 (5.4) |
| Waist circumference, cm | 95.2 (14.5) | 97.5 (14) | 98.5 (14.2) | 100 (14) | 99.5 (14.7) |
| Systolic blood pressure, mmHg | 124.8 (21.5) | 124.8 (20.8) | 126.6 (20.7) | 128.3 (21.6) | 128.4 (22.5) |
| Diastolic blood pressure, mmHg | 72.4 (10.2) | 71.6 (10.2) | 71.9 (9.8) | 72.1 (10.7) | 71.6 (10.4) |
| Biochemical | |||||
| HDL cholesterol, mg/dL | 51.7 (14.4) | 52 (15.8) | 50.7 (14.4) | 50.4 (14.8) | 50.1 (14.7) |
| LDL cholesterol, mg/dL | 117.9 (31.7) | 118 (31.7) | 118.2 (32.6) | 114.7 (31.5) | 115.4 (32.9) |
| Triglycerides, mg/dL | 127 (87.8) | 130.3 (96.8) | 133.5 (87.6) | 134.3 (82.1) | 132.8 (89.1) |
| Estimated glomerular filtration rate, mL/min/1.73m2 | 98.2 (14.8) | 93.4 (14.9) | 90.3 (16.6) | 86.2 (18) | 82.8 (21.7) |
| , n (%)Medical history | |||||
| Prevalent diabetes | 163 (12.1) | 159 (11.7) | 209 (15.4) | 212 (15.7) | 191 (14.1) |
| Lipid lowering medication | 188 (13.9) | 159 (11.7) | 218 (16.1) | 245 (18.1) | 244 (18) |
| Anti-hypertensive medication | 364 (26.9) | 434 (32.1) | 507 (37.4) | 590 (43.6) | 621 (45.9) |
| Antibiotics use in past 2 weeks | 50 (3.7) | 33 (2.4) | 38 (2.8) | 41 (3) | 42 (3.1) |
| eGFR, n (% <60) | 6 (0.4) | 24 (1.8) | 55 (4.1) | 96 (7.1) | 196 (14.5) |
| Dietary habits | |||||
| Fruits, servings/d | 1.9 (1.8) | 1.9 (1.6) | 1.9 (1.6) | 2 (1.7) | 1.9 (1.5) |
| Vegetables, servings/d | 1.9 (1.3) | 1.8 (1.3) | 1.9 (1.4) | 1.8 (1.4) | 1.9 (1.4) |
| Fiber, g/d | 18.8 (10.4) | 18.7 (10.4) | 18.9 (10.7) | 18.9 (10.4) | 18.2 (9.3) |
| Unprocessed and processed red meat, servings/d | 0.4 (0.6) | 0.5 (0.6) | 0.5 (0.6) | 0.5 (0.6) | 0.5 (0.5) |
| Poultry, servings/d | 0.3 (0.4) | 0.3 (0.4) | 0.3 (0.3) | 0.3 (0.3) | 0.3 (0.3) |
| Eggs, servings/d | 0.1 (0.2) | 0.1 (0.2) | 0.1 (0.3) | 0.1 (0.3) | 0.1 (0.3) |
| Fish, servings/d | 0.3 (0.4) | 0.2 (0.3) | 0.2 (0.3) | 0.2 (0.3) | 0.2 (0.3) |
| Q1 | Q2 | Q3 | Q4 | Q5 | -trendP | Continuous, per -IQRa | |
|---|---|---|---|---|---|---|---|
| Median TMAO, µmol/L | 1.75 | 2.61 | 3.56 | 4.98 | 9.2 | ||
| Total number of participants/ASCVD cases | 1351/73 | 1354/112 | 1354/180 | 1352/231 | 1354/256 | ||
| Person-years of follow-up | 18,445 | 18,429 | 18,014 | 17,459 | 17,128 | ||
| Hazard ratios (95% CI)b | |||||||
| Demographic-adjusted | REF | 1.06 (0.79, 1.42) | 1.25 (0.95, 1.64) | 1.36 (1.04, 1.78) | 1.51 (1.15, 1.97) | 0.0003 | 1.11 (1.05, 1.17) |
| Multivariable-adjusted | REF | 1.02 (0.76, 1.37) | 1.17 (0.89, 1.54) | 1.24 (0.94, 1.62) | 1.32 (1.01, 1.73) | 0.02 | 1.09 (1.03, 1.15) |
| Multivariable plus diet | REF | 1.02 (0.75, 1.37) | 1.17 (0.88, 1.54) | 1.23 (0.94, 1.62) | 1.33 (1.01, 1.74) | 0.01 | 1.09 (1.03, 1.15) |
Sensitivity analysis
| Hazard ratio (95% CI) per IQRa | |
|---|---|
| All (n=6,765, 852 cases) | 1.09 (1.03, 1.15) |
| Whites (n=2,607; 328 cases) | 0.96 (0.85, 1.09) |
| Blacks (n=1,868; 246 cases) | 1.10 (0.95, 1.26) |
| Hispanics (n=1,489; 200 cases) | 1.17 (1.07, 1.28) |
| Asians (n=801; 78 cases) | 1.24 (0.99, 1.54) |
Discussion
In this large, prospective, community-based cohort of multi-ethnic/racial backgrounds and with serial TMAO measures over time, higher plasma TMAO was associated with 32% higher risk of incident ASCVD comparing the highest quintile to the lowest quintile. This association was present after adjustment for sociodemographics, lifestyle habits, metabolic risk factors, blood lipids, and medication use. This included adjustment for dietary intakes of fruits, vegetables, and red meat, suggesting that the TMAO-ASCVD relationship extends beyond these factors. Importantly, the association with ASCVD remained significant after adjusting for smoking, diabetes, adiposity, blood pressure, and lipids, suggesting mechanisms linking TMAO and atherosclerotic risk beyond traditional risk factors.
A number of experimental studies support the biologic plausibility and potential causality of our observed associations. TMAO may increase atherosclerosis and plaque vulnerability through effects on inflammation31, oxidative stress, endothelial dysfunction, and thrombosis32. TMAO may also worsen glycemic control33 and promote metabolic dysfunction34, which may increase the risk of microvascular disease35 and macrovascular ASCVD. At the cellular level, TMAO promotes foam cell formation in artery walls by increasing expression of pro-atherogenic scavenger receptors36–38, reducing reverse cholesterol efflux2, and enhancing platelet reactivity through increased Ca2+ release from intracellular stores39. TMAO may also directly impact vascular endothelial cell Tissue Factor expression to heighten thrombotic potential25. Each of these multiple pathways could influence the development and incidence of ASCVD.
The present study represents a unique, community-based multi-ethnic population who were free of clinical ASCVD at baseline. Our finding of a positive association between TMAO and ASCVD in this community-based study supports and greatly extends the results of prior observational studies, many of which were in clinical samples of patients with preexisting disease43, –44) particularly since we evaluated a racially and ethnically diverse population and were also able to adjust for a wide variety comorbidities, risk factors, and social/demographic factors typically not available as covariates in most other studies (e.g. income, education, physical activity, and dietary habits). We also leveraged serial measures of TMAO, reducing misclassification due to changes in its levels over time. To our knowledge, only one prior study has reported on associations of serially measured TMAO with ASCVD, in the Cardiovascular Health Study (CHS) comprising adults age 65 + years at baseline45. In that study, higher long-term levels of plasma TMAO associated with higher risk of both incident ASCVD and recurrent ASCVD. In CHS, the highest quintile HR for incident CVD was 1.21 (95% CI: 1.02, 1.42), similar to our current results in MESA (HR: 1.33, 95% CI :1.02, 1.74).
In exploratory analyses by race and ethnicity, the association between TMAO and ASCVD was numerically larger among Hispanic and Asian participants as compared to White participants, but these differences between races/ethnicities were not statistically significant. To our knowledge, this is the first assessment of TMAO and incident ASCVD in a diverse multi-racial/ethnic cohort. Whether the potentially larger effects among Hispanic and Asian participants are due to chance, confounding, or biology needs further exploration in other cohorts and experimental studies. In a recent systematic review of ASCVD and TMAO, few studies evaluated TMAO and ASCVD in non-Caucasian populations, and these were generally small and limited to clinical cohorts with prevalent major clinical diseases49. –50)
In the current study, the TMAO-ASCVD association was attenuated after adjustment for eGFR; and also appeared possibly stronger in those with mildly reduced renal function at baseline (eGFR < 60). Because TMAO causally reduces eGFR, this could be a mediator in the causal pathway of its effects. Similar findings were seen in our prior work among older adults in CHS13,28,40–45, although only among individuals without prevalent ASCVD at baseline. Well established mechanistic evidence shows that TMAO can directly impair renal function. Feeding mice with choline or TMAO reduces GFR, raises plasma cystatin C and urine albumin levels, and increases tubulointerstitial fibrosis28,29. Moreover, these renal impairments can be prevented by targeted inhibition of gut microbial TMAO generation29,46. TMAO also reduces albumin uptake by human proximal tubular cells and suppresses expression of megalin, an albumin-binding surface receptor on tubular epithelial cells critical for urine protein reabsorption48. In line with these experimental findings, higher plasma TMAO levels associate with higher risk of incident CKD and decline in kidney function in community-based cohorts15. Our new findings support the need for further investigation of this interplay between diet, microbiome-related metabolites, renal decline, and ASCVD.
Our investigation has several strengths. The multi-racial and ethnic cohort across ages 45–84 years at baseline increases generalizability, and low loss to follow-up reduces potential for bias. The prospective design among individuals free of ASCVD allows assessment of temporality and minimizes reverse causation, while the population-based cohort design minimizes selection bias. The large sample size and extended follow-up provided a large number of events and statistical power to detect relevant associations. Information on a wide array of ASCVD risk measured using standardized methods11, facilitating multivariable adjustment to reduce confounding. ASCVD outcomes were identified and confirmed by a comprehensive review and centralized adjudication process, reducing the potential for missed or misclassified outcomes. The use of serial measures of TMAO with time-varying estimates reduced exposure misclassification from variations in TMAO concentrations over time. The time-varying Cox regression models appropriately allow adjustment for exposures and covariate values, including age, also increases the stability of the measure and thus the generalizability of the results, and potential clinical utility of the findings.
Potential limitations should be considered. Due to the observational nature of our study, residual confounding by unknown or unmeasured factors may be present. However, our results were robust to adjustment for multiple cardiovascular risk factors as well as sociodemographics and dietary and other lifestyle habits. Data on factors associated with TMAO production, such as composition of gut microbiota and hepatic flavin-containing monooxygenase 3 (FMO3) activity, were not collected, which should be considered in future studies. As TMAO levels were measured prospectively, before development of disease, any remaining within-individual variation is likely to attenuate findings toward the null, reducing the strength of observed associations. The population was U.S.-based; hence findings are not necessarily generalizable to other nations.
Several lines of thought suggest that TMAO accelerates atherosclerosis by reducing reverse cholesterol transport and promoting vascular inflammation, which can lead to lipid accumulation and progression of atherosclerosis. This is concordant with several recent meta-analysis that demonstrate an independent relationship between all-cause mortality, CVD mortality, major adverse cardiovascular events, hypertension, DM, and glomerular filtration rate51,52.
These new findings support the role of the diet-microbiome axis for atherosclerotic risk in multi-ethnic US populations, indicating a need to test dietary and pharmacologic interventions in individuals with elevated gut microbial metabolites like TMAO as a potential effective strategy in mitigating future ASCVD.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Supplementary Material 1
Supplementary Material 2